Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Finished Goods (2022 - 2026)

Gyre Therapeutics has reported Finished Goods over the past 4 years, most recently at $2.9 million for Q4 2025.

  • Quarterly Finished Goods rose 10.71% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 10.71% year-over-year, with the annual reading at $2.9 million for FY2025, 10.71% up from the prior year.
  • Finished Goods was $2.9 million for Q4 2025 at Gyre Therapeutics, down from $3.3 million in the prior quarter.
  • Over five years, Finished Goods peaked at $3.4 million in Q2 2025 and troughed at $1.4 million in Q4 2023.
  • The 4-year median for Finished Goods is $2.2 million (2024), against an average of $2.3 million.
  • Year-over-year, Finished Goods fell 2.43% in 2023 and then surged 122.77% in 2025.
  • A 4-year view of Finished Goods shows it stood at $1.4 million in 2022, then fell by 2.43% to $1.4 million in 2023, then soared by 91.5% to $2.6 million in 2024, then increased by 10.71% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Finished Goods are $2.9 million (Q4 2025), $3.3 million (Q3 2025), and $3.4 million (Q2 2025).